Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far

doi:10.4254/wjh.v12.i12.1182

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8447)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

452

WORD

143

HTML

4554

Figures (1-3)

529

Tables (1-1)

219

Sum=5897

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

253

Download

503

Sum=756

Publishing Process of This Article

Item

Count

Browse

580

Download

1214

Sum=1794

Dec 27, 2020 (publication date) through May 3, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Dec 27, 2020; 12(12): 1182-1197
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1182

Open in New Tab Full Size Figure Download Figure

Figure 1 Spectrum of medications used in coronavirus disease 2019 likely to cause liver injury. COVID-19: Coronavirus disease 2019; UDP-GT: UDP-glucuronosyltransferase; NAFLD: Nonalcoholic fatty liver disease.

Open in New Tab Full Size Figure Download Figure

Figure 2 Potential mechanisms of liver injury in coronavirus disease 2019. ACE2: Angiotensin converting enzyme 2; ARDS: Acute respiratory distress syndrome; CAMs: Complementary and alternative medicines; IL: Interleukin.

Open in New Tab Full Size Figure Download Figure

Figure 3 Approach to a coronavirus disease 2019 patient with liver dysfunction. COVID-19: Coronavirus disease 2019; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ACLF: Acute-on-chronic liver failure; USG: Ultrasonography.

Citation: Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far. World J Hepatol 2020; 12(12): 1182-1197
URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1182.htm
DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1182